These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30933552)

  • 1. The Clinical Utility of the Genomic Prostate Score in Men with Very Low to Intermediate Risk Prostate Cancer.
    Gaffney C; Golan R; Cantu MD; Scognamiglio T; McCarthy H; Mosquera JM; McClure TD; Barbieri CE; Robinson BD; Khani F
    J Urol; 2019 Jul; 202(1):96-101. PubMed ID: 30933552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
    Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
    J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stability of a 17-Gene Genomic Prostate Score in Serial Testing of Men on Active Surveillance for Early Stage Prostate Cancer.
    Cedars BE; Washington SL; Cowan JE; Leapman M; Tenggara I; Chan JM; Cooperberg MR; Carroll PR
    J Urol; 2019 Oct; 202(4):696-701. PubMed ID: 30958742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Biopsy-based 17-gene Genomic Prostate Score as a Predictor of Metastases and Prostate Cancer Death in Surgically Treated Men with Clinically Localized Disease.
    Van Den Eeden SK; Lu R; Zhang N; Quesenberry CP; Shan J; Han JS; Tsiatis AC; Leimpeter AD; Lawrence HJ; Febbo PG; Presti JC
    Eur Urol; 2018 Jan; 73(1):129-138. PubMed ID: 28988753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genomic Scores are Independent of Disease Volume in Men with Favorable Risk Prostate Cancer: Implications for Choosing Men for Active Surveillance.
    Nyame YA; Grimberg DC; Greene DJ; Gupta K; Kartha GK; Berglund R; Gong M; Stephenson AJ; Magi-Galluzzi C; Klein EA
    J Urol; 2018 Feb; 199(2):438-444. PubMed ID: 28941920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.
    Tosoian JJ; Chappidi MR; Bishoff JT; Freedland SJ; Reid J; Brawer M; Stone S; Schlomm T; Ross AE
    BJU Int; 2017 Dec; 120(6):808-814. PubMed ID: 28481440
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correlation of a Commercial Genomic Risk Classifier with Histological Patterns in Prostate Cancer.
    Greenland NY; Zhang L; Cowan JE; Carroll PR; Stohr BA; Simko JP
    J Urol; 2019 Jul; 202(1):90-95. PubMed ID: 30810466
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy.
    Patel HD; Gupta M; Tosoian JJ; Carter HB; Partin AW; Epstein JI
    J Urol; 2018 Nov; 200(5):1068-1074. PubMed ID: 29673946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Pathological and Oncologic Outcomes of Favorable Risk Gleason Score 3 + 4 and Low Risk Gleason Score 6 Prostate Cancer: Considerations for Active Surveillance.
    Gearman DJ; Morlacco A; Cheville JC; Rangel LJ; Karnes RJ
    J Urol; 2018 May; 199(5):1188-1195. PubMed ID: 29225057
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Active Surveillance for Men with Intermediate Risk Prostate Cancer.
    Agrawal V; Ma X; Hu JC; Barbieri CE; Nagar H
    J Urol; 2021 Jan; 205(1):115-121. PubMed ID: 32658588
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NCCN Risk Reclassification in Black Men with Low and Intermediate Risk Prostate Cancer After Genomic Testing.
    Seiden B; Weng S; Sun N; Gordon D; Harris WN; Barnett J; Myrie A; Jones T; Pak SY; Fudl A; Shields J; McNeil BK; Weiss JP; Smith MT; Esdaille AR; Winer AG
    Urology; 2022 May; 163():81-89. PubMed ID: 34688772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
    Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
    J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of early transperineal template-guided prostate biopsy for risk stratification in men undergoing active surveillance for prostate cancer.
    Voss J; Pal R; Ahmed S; Hannah M; Jaulim A; Walton T
    BJU Int; 2018 Jun; 121(6):863-870. PubMed ID: 29239082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of the Decipher Test for predicting adverse pathology in candidates for prostate cancer active surveillance.
    Kim HL; Li P; Huang HC; Deheshi S; Marti T; Knudsen B; Abou-Ouf H; Alam R; Lotan TL; Lam LLC; du Plessis M; Davicioni E; Fleshner N; Lane BR; Ross AE; Davis JW; Mohler JL; Trock BJ; Klein EA; Tosoian JJ; Hyndman ME; Bismar TA
    Prostate Cancer Prostatic Dis; 2019 Sep; 22(3):399-405. PubMed ID: 30542054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving risk stratification among veterans diagnosed with prostate cancer: impact of the 17-gene prostate score assay.
    Lynch JA; Rothney MP; Salup RR; Ercole CE; Mathur SC; Duchene DA; Basler JW; Hernandez J; Liss MA; Porter MP; Wright JL; Risk MC; Garzotto M; Efimova O; Barrett L; Berse B; Kemeter MJ; Febbo PG; Dash A
    Am J Manag Care; 2018 Jan; 24(1 Suppl):S4-S10. PubMed ID: 29337486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate biopsy histopathologic features correlate with a commercial gene expression assay's reclassification of patient NCCN risk category.
    Greenland NY; Cowan JE; Chan E; Carroll PR; Stohr BA; Simko JP
    Prostate; 2020 Dec; 80(16):1421-1428. PubMed ID: 32946625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biopsy Core Features are Poor Predictors of Adverse Pathology in Men with Grade Group 1 Prostate Cancer.
    Audenet F; Vertosick EA; Fine SW; Sjoberg DD; Vickers AJ; Reuter VE; Eastham JA; Scardino PT; Touijer KA
    J Urol; 2018 Apr; 199(4):961-968. PubMed ID: 29030317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expressed prostatic secretion biomarkers improve stratification of NCCN active surveillance candidates: performance of secretion capacity and TMPRSS2:ERG models.
    Whelan C; Kawachi M; Smith DD; Linehan J; Babilonia G; Mejia R; Wilson T; Smith SS
    J Urol; 2014 Jan; 191(1):220-6. PubMed ID: 23669563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.